Click here to view the original post by The American Academy of Ophthalmology.
In addition to our own original articles, the Retina Consultant team expertly curates relevant news and research from leading publications.to provide our readers with a comprehensive view of the retina & ophthalmology landscape, Full credit belongs to the original authors and publication.
By clicking the link above, you will be leaving our site to view an article from its original source.
Sharpen your perspective. Get our weekly analysis of the news shaping the retina industry.
In patients with macular telangiectasia type 2 (MacTel 2), slower ellipsoid zone loss was seen after implantation of a novel ciliary neurotrophic factor (CNTF)–based therapeutic device.